Research Topics
Species | C H MillerSummaryAffiliation: Centers for Disease Control and Prevention Country: USA Publications
| Collaborators
|
Detail Information
Publications
Validation of Nijmegen-Bethesda assay modifications to allow inhibitor measurement during replacement therapy and facilitate inhibitor surveillanceC H Miller
Division of Blood Disorders, National Center on Birth Defects and Developmental Disabilities, Centers for Disease Control and Prevention, Atlanta, GA 30333, USA
J Thromb Haemost 10:1055-61. 2012..As part of a pilot U.S. inhibitor surveillance project initiated at the Centers for Disease Control and Prevention (CDC) in 2006, a centralized inhibitor measurement was instituted...- F8 and F9 mutations in US haemophilia patients: correlation with history of inhibitor and race/ethnicityC H Miller
Division of Blood Disorders, National Center on Birth Defects and Developmental Disabilities, Centers for Disease Control and Prevention, Atlanta, GA 30333, USA
Haemophilia 18:375-82. 2012..White patients with history of inhibitor did not exhibit rare F8 haplotypes. F8 gene analysis did not reveal a cause for the higher inhibitor frequencies in Black and Hispanic patients... - The spectrum of haemostatic characteristics of women with unexplained menorrhagiaC H Miller
Division of Blood Disorders, National Center on Birth Defects and Developmental Disabilities, Centers for Disease Control and Prevention, Atlanta, GA 30333, USA
Haemophilia 17:e223-9. 2011..S. sites. To what degree these abnormalities are clinically significant requires further study... 
Laboratory tests for the diagnosis of thrombotic disordersConnie H Miller
Division of Hereditary Blood Disorders, National Center on Birth Defects and Developmental Disabilities, Centers for Disease Control and Prevention, Atlanta, Georgia 30345, USA
Clin Obstet Gynecol 49:844-9. 2006..These changes make some thrombotic disorders difficult to diagnose during pregnancy. Testing before pregnancy for women with a personal or family history of thrombosis will simplify the interpretation...- Elevated factor VII as a risk factor for recurrent fetal loss. Relationship to factor VII gene polymorphismsConnie H Miller
Division of Hereditary Blood Disorders, National Center on Birth Defects and Developmental Disabilities, Centers for Disease Control and Prevention, 1600 Clifton Road, Mailstop D 02, Atlanta, Georgia 30333, USA
Thromb Haemost 93:1089-94. 2005..No other promoter polymorphisms were identified. This is the first report of a significant elevation of FVII in a population with recurrent fetal loss. These data suggest the need for further investigation of this potential risk factor... - Population differences in von Willebrand factor levels affect the diagnosis of von Willebrand disease in African-American womenC H Miller
Hematologic Diseases Branch, National Center for Infectious Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia 30333, USA
Am J Hematol 67:125-9. 2001..The finding of increased vWF:Ag not accompanied by increased vWF:RCof has implications for understanding the structure-function relationships of vWF. Published 2001 Wiley-Liss, Inc... - In non-severe hemophilia A the risk of inhibitor after intensive factor treatment is greater in older patients: a case-control studyC L Kempton
Aflac Cancer Center and Blood Disorders Service and Department of Hematology and Medical Oncology, Emory University, Atlanta, GA, USA
J Thromb Haemost 8:2224-31. 2010..Although intensive FVIII treatment has long been considered a risk factor for inhibitor development in those with non-severe disease, its strength of association and the influence of other factors have remained undefined... - Evaluation of two automated methods for measurement of the ristocetin cofactor activity of von Willebrand factorConnie H Miller
Hematologic Diseases Branch, National Center for Infectious Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia, USA
Thromb Haemost 88:56-9. 2002..93. The CDC in-house method was compared to the BC Reagent method in 79 additional menorrhagia cases, with r = .94. The automated methods produced results equivalent or superior to those of traditional methods of measuring VWF:RCo... - Factor V Leiden and factor V R2 allele: high-throughput analysis and association with venous thromboembolismJ M Benson
Hematologic Diseases Branch, Division of AIDS, STD, and TB Laboratory Research, National Center for Infectious Diseases, Centers for Disease Control and Prevention, Atlanta, GA 30333, USA
Thromb Haemost 86:1188-92. 2001..S. Caucasians, 5.6% in African-Americans, 13.4% in Asian or Pacific Islanders and 11.3% in Hispanics. No association between venous thromboembolism and the R2 allele was noted, and furthermore no interaction with FV Leiden was observed... - Measurement of von Willebrand factor activity: relative effects of ABO blood type and raceC H Miller
Hematologic Diseases Branch, NCID DASTLR, Centers for Disease Control and Prevention, 1600 Clifton Road, Mailstop D 02, Atlanta, GA 30333, USA
J Thromb Haemost 1:2191-7. 2003..This heterogeneity within the normal population is partially responsible for the difficulty in defining diagnostic limits for von Willebrand disease... - Age and the prevalence of bleeding disorders in women with menorrhagiaClaire S Philipp
Department of Medicine, UMDNJ Robert Wood Johnson Medical School, New Brunswick, New Jersey, USA
Obstet Gynecol 105:61-6. 2005..A study was conducted to evaluate the frequency and types of hemostatic defects occurring in adolescent and perimenopausal-age women diagnosed with menorrhagia... - Changes in von Willebrand factor and factor VIII levels during the menstrual cycleConnie H Miller
Thromb Haemost 87:1082-3. 2002